Tag: Apoptosis
Survivin
Survivin (BIRC5) is a tumour‑specific IAP that integrates apoptosis suppression with essential mitotic functions. As part of the chromosomal passenger complex, Survivin ensures proper chromosome segregation while stabilising anti‑apoptotic pathways, making it a central driver of tumour progression and therapy resistance.
Livin (ML‑IAP)
Livin (ML‑IAP) is a tumour‑specific inhibitor of apoptosis that blocks caspase activity and ubiquitinates pro‑apoptotic proteins. Its splice variants, Livin‑α and Livin‑β, differ in potency, and its unique ability to switch from anti‑apoptotic to pro‑apoptotic after cleavage makes Livin a key regulator of tumour survival and therapy resistance.
cIAP2
cIAP2 is a ubiquitin ligase that regulates TNF receptor signalling, non‑canonical NF‑κB activation and NOD2‑mediated immune responses. By controlling RIPK1, RIPK2 and NIK stability, cIAP2 determines whether cells activate survival pathways or transition into apoptosis, making it essential in inflammation and cancer biology.
cIAP1
cIAP1 is a ubiquitin ligase that regulates TNF receptor signalling and determines whether cells activate NF‑κB survival pathways or switch into apoptosis or necroptosis. By controlling RIPK1 ubiquitination and cooperating with TRAF2, cIAP1 plays essential roles in inflammation, immunity and cancer biology.
Survivin
Survivin (BIRC5) is a tumour‑specific IAP that integrates apoptosis suppression with essential mitotic functions. As part of the chromosomal passenger complex, Survivin ensures proper chromosome segregation while stabilising anti‑apoptotic pathways, making it a central driver of tumour progression and therapy resistance.
Livin (ML‑IAP)
Livin (ML‑IAP) is a tumour‑specific inhibitor of apoptosis that blocks caspase activity and ubiquitinates pro‑apoptotic proteins. Its splice variants, Livin‑α and Livin‑β, differ in potency, and its unique ability to switch from anti‑apoptotic to pro‑apoptotic after cleavage makes Livin a key regulator of tumour survival and therapy resistance.
cIAP2
cIAP2 is a ubiquitin ligase that regulates TNF receptor signalling, non‑canonical NF‑κB activation and NOD2‑mediated immune responses. By controlling RIPK1, RIPK2 and NIK stability, cIAP2 determines whether cells activate survival pathways or transition into apoptosis, making it essential in inflammation and cancer biology.
cIAP1
cIAP1 is a ubiquitin ligase that regulates TNF receptor signalling and determines whether cells activate NF‑κB survival pathways or switch into apoptosis or necroptosis. By controlling RIPK1 ubiquitination and cooperating with TRAF2, cIAP1 plays essential roles in inflammation, immunity and cancer biology.